Хайлтын үр дүнгүүд - David Fitchett

Үр дүнг сайжруулах
  1. 1
    Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice

    Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice -н David Fitchett

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Noninvasive determination of aortic input impedance and external left ventricular power output: A validation and repeatability study of a new technique

    Noninvasive determination of aortic input impedance and external left ventricular power output: A validation and repeatability study of a new technique -н Raymond P. Kelly, David Fitchett

    Хэвлэсэн 1992
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Statin Intolerance

    Statin Intolerance -н David Fitchett, Robert A. Hegele, Subodh Verma

    Хэвлэсэн 2015
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes

    Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes -н David Fitchett, Jacob A. Udell, Silvio E. Inzucchi

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Right ventricular dilated cardiomyopathy.

    Right ventricular dilated cardiomyopathy. -н David Fitchett, D. Sugrue, Colin Macarthur, C M Oakley

    Хэвлэсэн 1984
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

    Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® t... -н Naveed Sattar, David Fitchett, Stefan Hantel, Jyothis T. George, Bernard Zinman

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

    The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis -н Sophie A. Jamal, David Fitchett, Charmaine E. Lok, David C. Mendelssohn, Ross T. Tsuyuki

    Хэвлэсэн 2009
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Resting heart rate: A modifiable prognostic indicator of cardiovascular risk and outcomes?

    Resting heart rate: A modifiable prognostic indicator of cardiovascular risk and outcomes? -н J. Malcolm O. Arnold, David Fitchett, Jonathan G. Howlett, Eva Lonn, Jean‐Claude Tardif

    Хэвлэсэн 2008
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

    Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus -н Hiddo J.L. Heerspink, Bruce A. Perkins, David Fitchett, Mansoor Husain, David Z.I. Cherney

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes

    Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes -н Subodh Verma, Christoph Wanner, Isabella Zwiener, Anne Pernille Ofstad, Jyothis T. George, David Fitchett, Bernard Zinman

    Хэвлэсэн 2019
    Бүрэн текст авах
    Carta
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®

    Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME® -н Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Uwe Hehnke, Jyothis T. George, Odd Erik Johansen, David Fitchett

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

    Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG... -н Subodh Verma, C. David Mazer, David Fitchett, Silvio E. Inzucchi, Egon Pfarr, Jyothis T. George, Bernard Zinman

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

    Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control -н Silvio E. Inzucchi, Mikhail Kosiborod, David Fitchett, Christoph Wanner, Uwe Hehnke, Stefan Kaspers, Jyothis T. George, Bernard Zinman

    Хэвлэсэн 2018
    Бүрэн текст авах
    Carta
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better

    Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better -н Andrew T. Yan, Raymond T. Yan, Mary Tan, Amparo Casanova, Marino Labinaz, K Sridhar, David Fitchett, Anatoly Langer, Shaun G. Goodman

    Хэвлэсэн 2007
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    Applying the Evidence

    Applying the Evidence -н Gustavo Saposnik, Shaun G. Goodman, Lawrence A. Leiter, Raymond T. Yan, David Fitchett, Neville Bayer, Amparo Casanova, Anatoly Langer, Andrew T. Yan

    Хэвлэсэн 2009
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

    Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial -н Pedro Monteiro, Richard M. Bergenstal, Elvira Toural, Silvio E. Inzucchi, Bernard Zinman, Stefan Hantel, Sanja Giljanovic Kiš, Stefan Kaspers, Jyothis T. George, David Fitchett

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

    SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials -н Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, H.J. Woerle, Uli C. Broedl, Odd Erik Johansen

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  18. 18
    Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME<sup>®</sup>trial

    Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME<sup>®</sup>trial -н David Fitchett, Bernard Zinman, Christoph Wanner, John M. Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Errata/Corrigenda
    Жагсаалт руу хадгалах
    -д хадгалсан:
  19. 19
    Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

    Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease -н Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, David Fitchett, Michaela Mattheus, Jyothis T. George, Hans J. Woerle, Uli C. Broedl, Maximilian von Eynatten, Bernard Zinman

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  20. 20
    Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

    Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure -н Javed Butler, Faı̈ez Zannad, David Fitchett, Bernard Zinman, Audrey Koitka‐Weber, Maximilian von Eynatten, Isabella Zwiener, Jyothis T. George, Martina Brueckmann, Alfred K. Cheung, Christoph Wanner

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: